Home Novartis announces FDA approval of Entresto to reduce risk of...
 

Keywords :   


Novartis announces FDA approval of Entresto to reduce risk of...

2015-07-09 05:43:33| Biotech - Topix.net

Novartis announced today that the US Food and Drug Administration has approved Entresto tablets, previously known as LCZ696, to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure and reduced ejection fraction . It is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other angiotensin receptor blocker .

Tags: of risk reduce approval

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
16.06Eastern North Pacific Tropical Weather Outlook
16.06Atlantic Tropical Weather Outlook
16.06Weekly Recap: U.S. House Approves WIPPES Legislation, Drylock Holds Private Label Academy & More
16.06Atlantic Tropical Weather Outlook
16.06Eastern North Pacific Tropical Weather Outlook
16.06Atlantic Tropical Weather Outlook
16.06Eastern North Pacific Tropical Weather Outlook
15.06Atlantic Tropical Weather Outlook
More »